Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma

Satoshi Yamasaki, Dai Chihara, Sung Won Kim, Takahito Kawata, Shuichi Mizuta, Hiroatsu Ago, Takaaki Chou, Takahisa Yamane, Hitoji Uchiyama, Tatsuo Oyake, Katsuhiro Miura, Bungo Saito, Hirofumi Taji, Hirohisa Nakamae, Toshihiro Miyamoto, Takahiro Fukuda, Junya Kanda, Yoshiko Atsuta, Ritsuro Suzuki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n = 112 and 75) or primary induction failure (PIF; n = 127 and 83) between 2000 and 2015. Significant risk factors for overall survival (OS) after upfront ASCT were a ≥ 2 prognostic index for T-cell lymphoma (P < 0.001) and partial response (PR) at ASCT (P = 0.041) in PTCL-NOS patients, and > 60 years of age (P = 0.0028) and PR at ASCT (P = 0.0013) in AITL patients. Performance status of ≥ 2 at ASCT (P < 0.001), receiving ≥ 3 regimens before ASCT (P = 0.018), and PR at ASCT (P = 0.018) in PTCL-NOS patients and > 60 years of age at ASCT (P = 0.0077) in AITL patients were risk factors for OS after ASCT with a chemosensitive PIF status. Strategies that carefully select PTCL patients may allow identification of individuals suitable for ASCT.

Original languageEnglish
Pages (from-to)175-186
Number of pages12
JournalInternational journal of hematology
Volume109
Issue number2
DOIs
Publication statusPublished - Feb 20 2019

Fingerprint

Peripheral T-Cell Lymphoma
Stem Cell Transplantation
T-Cell Lymphoma
Drug Therapy
Survival
Complementary Therapies
Retrospective Studies
Recurrence

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. / Yamasaki, Satoshi; Chihara, Dai; Kim, Sung Won; Kawata, Takahito; Mizuta, Shuichi; Ago, Hiroatsu; Chou, Takaaki; Yamane, Takahisa; Uchiyama, Hitoji; Oyake, Tatsuo; Miura, Katsuhiro; Saito, Bungo; Taji, Hirofumi; Nakamae, Hirohisa; Miyamoto, Toshihiro; Fukuda, Takahiro; Kanda, Junya; Atsuta, Yoshiko; Suzuki, Ritsuro.

In: International journal of hematology, Vol. 109, No. 2, 20.02.2019, p. 175-186.

Research output: Contribution to journalArticle

Yamasaki, S, Chihara, D, Kim, SW, Kawata, T, Mizuta, S, Ago, H, Chou, T, Yamane, T, Uchiyama, H, Oyake, T, Miura, K, Saito, B, Taji, H, Nakamae, H, Miyamoto, T, Fukuda, T, Kanda, J, Atsuta, Y & Suzuki, R 2019, 'Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma', International journal of hematology, vol. 109, no. 2, pp. 175-186. https://doi.org/10.1007/s12185-018-2560-x
Yamasaki, Satoshi ; Chihara, Dai ; Kim, Sung Won ; Kawata, Takahito ; Mizuta, Shuichi ; Ago, Hiroatsu ; Chou, Takaaki ; Yamane, Takahisa ; Uchiyama, Hitoji ; Oyake, Tatsuo ; Miura, Katsuhiro ; Saito, Bungo ; Taji, Hirofumi ; Nakamae, Hirohisa ; Miyamoto, Toshihiro ; Fukuda, Takahiro ; Kanda, Junya ; Atsuta, Yoshiko ; Suzuki, Ritsuro. / Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. In: International journal of hematology. 2019 ; Vol. 109, No. 2. pp. 175-186.
@article{04e9fe070e1943a7a8db27d8829e3722,
title = "Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma",
abstract = "High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n = 112 and 75) or primary induction failure (PIF; n = 127 and 83) between 2000 and 2015. Significant risk factors for overall survival (OS) after upfront ASCT were a ≥ 2 prognostic index for T-cell lymphoma (P < 0.001) and partial response (PR) at ASCT (P = 0.041) in PTCL-NOS patients, and > 60 years of age (P = 0.0028) and PR at ASCT (P = 0.0013) in AITL patients. Performance status of ≥ 2 at ASCT (P < 0.001), receiving ≥ 3 regimens before ASCT (P = 0.018), and PR at ASCT (P = 0.018) in PTCL-NOS patients and > 60 years of age at ASCT (P = 0.0077) in AITL patients were risk factors for OS after ASCT with a chemosensitive PIF status. Strategies that carefully select PTCL patients may allow identification of individuals suitable for ASCT.",
author = "Satoshi Yamasaki and Dai Chihara and Kim, {Sung Won} and Takahito Kawata and Shuichi Mizuta and Hiroatsu Ago and Takaaki Chou and Takahisa Yamane and Hitoji Uchiyama and Tatsuo Oyake and Katsuhiro Miura and Bungo Saito and Hirofumi Taji and Hirohisa Nakamae and Toshihiro Miyamoto and Takahiro Fukuda and Junya Kanda and Yoshiko Atsuta and Ritsuro Suzuki",
year = "2019",
month = "2",
day = "20",
doi = "10.1007/s12185-018-2560-x",
language = "English",
volume = "109",
pages = "175--186",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma

AU - Yamasaki, Satoshi

AU - Chihara, Dai

AU - Kim, Sung Won

AU - Kawata, Takahito

AU - Mizuta, Shuichi

AU - Ago, Hiroatsu

AU - Chou, Takaaki

AU - Yamane, Takahisa

AU - Uchiyama, Hitoji

AU - Oyake, Tatsuo

AU - Miura, Katsuhiro

AU - Saito, Bungo

AU - Taji, Hirofumi

AU - Nakamae, Hirohisa

AU - Miyamoto, Toshihiro

AU - Fukuda, Takahiro

AU - Kanda, Junya

AU - Atsuta, Yoshiko

AU - Suzuki, Ritsuro

PY - 2019/2/20

Y1 - 2019/2/20

N2 - High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n = 112 and 75) or primary induction failure (PIF; n = 127 and 83) between 2000 and 2015. Significant risk factors for overall survival (OS) after upfront ASCT were a ≥ 2 prognostic index for T-cell lymphoma (P < 0.001) and partial response (PR) at ASCT (P = 0.041) in PTCL-NOS patients, and > 60 years of age (P = 0.0028) and PR at ASCT (P = 0.0013) in AITL patients. Performance status of ≥ 2 at ASCT (P < 0.001), receiving ≥ 3 regimens before ASCT (P = 0.018), and PR at ASCT (P = 0.018) in PTCL-NOS patients and > 60 years of age at ASCT (P = 0.0077) in AITL patients were risk factors for OS after ASCT with a chemosensitive PIF status. Strategies that carefully select PTCL patients may allow identification of individuals suitable for ASCT.

AB - High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n = 112 and 75) or primary induction failure (PIF; n = 127 and 83) between 2000 and 2015. Significant risk factors for overall survival (OS) after upfront ASCT were a ≥ 2 prognostic index for T-cell lymphoma (P < 0.001) and partial response (PR) at ASCT (P = 0.041) in PTCL-NOS patients, and > 60 years of age (P = 0.0028) and PR at ASCT (P = 0.0013) in AITL patients. Performance status of ≥ 2 at ASCT (P < 0.001), receiving ≥ 3 regimens before ASCT (P = 0.018), and PR at ASCT (P = 0.018) in PTCL-NOS patients and > 60 years of age at ASCT (P = 0.0077) in AITL patients were risk factors for OS after ASCT with a chemosensitive PIF status. Strategies that carefully select PTCL patients may allow identification of individuals suitable for ASCT.

UR - http://www.scopus.com/inward/record.url?scp=85056628705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056628705&partnerID=8YFLogxK

U2 - 10.1007/s12185-018-2560-x

DO - 10.1007/s12185-018-2560-x

M3 - Article

VL - 109

SP - 175

EP - 186

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -